Ovestin (Estriol)

Estriol binds to estrogen receptors in the vaginal and uterine tissues, stimulating cellular proliferation and increasing blood flow. This localized estrogenic activity promotes tissue regeneration, enhances mucosal hydration, and alleviates atrophic changes without producing strong systemic effects.

The dosage of Ovestin is determined by the prescribing healthcare professional based on the patient’s condition, severity of symptoms, and individual response. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Estriol is generally not recommended for use during pregnancy or while breastfeeding because the safety profile has not been established for these populations. Women who are pregnant, planning to become pregnant, or nursing should discuss alternative treatments with their healthcare provider.

To order Ovestin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with stronger estrogens such as estradiol, estriol in Ovestin offers a milder systemic effect and is often preferred for localized vaginal treatment. It provides effective symptom relief with a lower risk of systemic estrogen‑related adverse events, making it suitable for women who need targeted therapy.

Ovestin should be stored at room temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Ensure the container is tightly closed to maintain product stability and prevent contamination.

Ovestin is applied topically to the vaginal area, typically using a calibrated applicator or measured dose as instructed by the prescriber. The patient should follow the recommended frequency and duration of treatment for optimal results.

Serious risks include endometrial hyperplasia or carcinoma, thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, and rare allergic reactions. Patients should be monitored regularly for any signs of these conditions and report symptoms promptly.

Ovestin is contraindicated in women with a history of estrogen‑dependent cancers, active or past thromboembolic disease, uncontrolled hypertension, liver disease, or known hypersensitivity to estriol or any excipients in the formulation.